Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
Real-time Quote. Real-time CHI-X - 10/16 11:30:00 am
7.67 EUR   -2.79%
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate, PXL065
AQ
08/26POXEL : Half-year results
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Poxel : Announces its Financial Calendar for 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2019 | 04:34pm EDT

Lyon, France, January 29, 2019 - POXEL S.A. (Euronext - POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-

alcoholic steatohepatitis (NASH), today announced its schedule for the publication of financial information for 2019.

Event

Date*

2018 Fourth Quarter Financial Update

February 12, 2019

2018 Full Year Statement

March 21, 2019

2019 First Quarter Financial Update

April 8, 2019

2019 Second Quarter Financial Update

July 15, 2019

2019 First Half Statement

August 26, 2019

2019 Third Quarter Financial Update

October 7, 2019

2019 Fourth Quarter Financial Update

February 12, 2020

*Subject to modification

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin's development and commercialization in countries outside of Poxel's partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

Contacts
Poxel SA
Jonae R. BarnesSenior Vice President, Investor Relations and Public Relationsjonae.barnes@poxelpharma.com+1 617 818 2985

Investor relations / Media - EU/US
Trophic Communications
Gretchen Schweitzer or Stephanie May
may@trophic.eu +49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France
NewCap
Alexia Faure/Nicolas Merigeau
poxel@newcap.eu
+33 1 44 71 94 94

Released January 29, 2019

Disclaimer

Poxel SA published this content on 29 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 29 January 2019 21:33:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on POXEL
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/26POXEL : Half-year results
CO
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15POXEL : 2nd quarter earnings
CO
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
06/25POXEL : and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results ..
PU
04/10Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Im..
AQ
04/08POXEL : Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Tr..
PU
More news
Financials (EUR)
Sales 2019 40,0 M
EBIT 2019 -17,5 M
Net income 2019 -15,1 M
Finance 2019 33,4 M
Yield 2019 -
P/E ratio 2019 -13,1x
P/E ratio 2020 -5,59x
EV / Sales2019 4,21x
EV / Sales2020 7,15x
Capitalization 202 M
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 7,80  €
Spread / Highest target 118%
Spread / Average Target 94,0%
Spread / Lowest Target 75,6%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Christophe Arbet-Engels Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
POXEL53.24%225
GILEAD SCIENCES4.48%82 700
VERTEX PHARMACEUTICALS6.29%45 274
REGENERON PHARMACEUTICALS-19.84%33 245
WUXI APPTEC CO., LTD.64.57%20 149
GENMAB30.26%13 356